Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc phosphodiesterase ELAC protein 1 (ELAC1) is a cytosolic and nucleoplasmic enzyme that functions as a tRNA 3'-processing endoribonuclease, specifically cleaving the 3' trailer sequence in tRNA precursors[1][4][5][7]. ELAC1 plays a critical role in tRNA maturation, distinct from the longer isoform ELAC2 which carries out similar processes in the nucleus and mitochondria[1]. ELAC1 is also implicated in the rescue and recycling of tRNA molecules during ribosome-associated quality control, removing aberrant 2',3'-cyclic phosphates and enabling re-addition of the terminal CCA sequence needed for functional tRNA[1][3][4]. ELAC1 belongs to the RNase Z family and contains zinc-binding motifs characteristic of phosphodiesterases[6][7]. There are no significant reports of drug interactions, biomarker status, or safety concerns, and it is not currently considered a major therapeutic target in human disease[4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc phosphodiesterase ELAC protein 1 (ELAC1).